The Neuromyelitis Optica Spectrum Disorder market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Neuromyelitis Optica Spectrum Disorder: An Overview
Neuromyelitis Optica Spectrum Disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks) but, after the initial episode, no recurrence.
Neuromyelitis Optica Spectrum Disorder Market Key Facts
-
More than 95% of patients with NMOSD report no relatives with the disease, but approximately 3% report having other relatives with the condition. There is a strong association with a personal or family history of autoimmunity, which are present in 50% of cases. NMOSD is regarded as an autoimmune disease though the exact cause for the autoimmunity is unknown.
-
According to the Orphanet, NMO has a worldwide distribution and estimated prevalence of 1-2/100,000.
-
Neuromyelitis Optica Spectrum Disorder is more common among females as compared to males.
-
According to the “Siegel Rare Neuroimmune Association”, NMOSD can affect children as young as 3 years and adults as old as 90 years. The onset of NMOSD varies from childhood to adulthood, and the average age of onset is about 40.
Neuromyelitis Optica Spectrum Disorder Market
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Neuromyelitis Optica Spectrum Disorder market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the NMOSD market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Neuromyelitis Optica Spectrum Disorder Epidemiology
The epidemiology section covers insights into the historical and current NMOSD patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Neuromyelitis Optica Spectrum Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the NMOSD market or expected to get launched in the market during the study period. The analysis covers Neuromyelitis Optica Spectrum Disorder market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Neuromyelitis Optica Spectrum Disorder Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market
Neuromyelitis Optica Spectrum Disorder Therapeutics Analysis
The Neuromyelitis Optica Spectrum Disorder market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period.
Some of the key companies in the Neuromyelitis Optica Spectrum Disorder (NMOSD) market include:
-
Chugai
-
Roche
-
Bio-Thera Solutions
-
Remegen
-
Harbour BioMed
And many others
Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapies covered in the report include:
-
Satralizumab
-
BAT4406F
-
RC18
-
HBM9161
And many others
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market
Table of Content
1. Key Insights
2. Executive Summary
3. Neuromyelitis Optica Spectrum Disorder Competitive Intelligence Analysis
4. Neuromyelitis Optica Spectrum Disorder Market Overview at a Glance
5. Neuromyelitis Optica Spectrum Disorder Disease Background and Overview
6. Neuromyelitis Optica Spectrum Disorder Patient Journey
7. Neuromyelitis Optica Spectrum Disorder Epidemiology and Patient Population
8. Neuromyelitis Optica Spectrum Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Neuromyelitis Optica Spectrum Disorder Unmet Needs
10. Key Endpoints of Neuromyelitis Optica Spectrum Disorder Treatment
11. Neuromyelitis Optica Spectrum Disorder Marketed Products
12. Neuromyelitis Optica Spectrum Disorder Emerging Therapies
13. Neuromyelitis Optica Spectrum Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Neuromyelitis Optica Spectrum Disorder Market Outlook (7 major markets)
16. Neuromyelitis Optica Spectrum Disorder Access and Reimbursement Overview
17. KOL Views on the Neuromyelitis Optica Spectrum Disorder Market.
18. Neuromyelitis Optica Spectrum Disorder Market Drivers
19. Neuromyelitis Optica Spectrum Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market
Other Latest Reports By DelveInsight
Adenosine Deaminase-Severe Combined Immunodeficiency Market
DelveInsight’s “Adenosine Deaminase-Severe Combined Immunodeficiency Market” report delivers an in-depth understanding of the historical and forecasted epidemiology, the market size, shares, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies in the therapeutic domain.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/